The abstract is read at the publisher; the summary is JClub's.
Entirely virus-free CAR T cells with synthetic CAR DNA inserted at TRAC or CD3ζ loci show in vitro cytotoxicity comparable to lentiviral universal 41BB-CD3ζ CAR T cells, but xenograft leukemia control is not superior.
- Why it matters: Vector supply limits can bottleneck CAR T access, motivating off-the-shelf “universal” donor cells and alternative manufacturing that avoids viral reagents.
- What they did: The study directly compared non-viral genome editing insertion at TRAC or CD3ζ versus lentiviral-generated universal 41BB-CD3ζ CAR T cells, assessing cytotoxicity in vitro and human leukemia inhibition in xenograft murine models.
- The result: Non-viral manufacture achieved functional CAR T cells, yet in vivo leukemia inhibition in xenograft models was not better than lentiviral products, supporting careful benchmarking in preclinical and clinical testing.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.